A woman in her late forties sits across from me and describes, with obvious embarrassment, losing the thread of a sentence in a meeting she was running. She has lost words she has used for twenty years. She walks into rooms with no idea why. She is certain something is seriously wrong, and she has usually already been told by someone that it is just stress.
She is right that something is happening. She is usually wrong about what it is.
Cognitive change during perimenopause is one of the most consistently dismissed symptoms in medicine, and one of the most consistently catastrophized by the women experiencing it. Both responses are avoidable with accurate information.
The Short Answer
Memory and concentration difficulties during perimenopause are real, measurable, and common — affecting roughly two-thirds of women during the transition. For most women they are transient, improving in the years after the final menstrual period.
The changes are driven only partly by estradiol acting on the brain directly. A large share is driven by things the hormonal transition causes — disrupted sleep, night sweats, new-onset mood symptoms, iron deficiency from heavy bleeding — and those causes are treatable.
Hormone therapy is an effective treatment for hot flashes, night sweats, and the sleep disruption they cause, and relieving those symptoms often improves how a woman thinks and functions. Hormone therapy is not recommended as a treatment or preventive for cognitive decline or dementia. Those are two different claims and conflating them is the source of most of the confusion in this area.
Is Memory Loss During Perimenopause Normal?
Yes — and this is not merely reassurance, it is measurable.
The Study of Women’s Health Across the Nation, which followed a large, diverse cohort of women through the menopausal transition, found genuine declines in verbal memory and processing speed during perimenopause when women were tested formally. Importantly, the same work found that performance largely recovered in postmenopause. Women were not imagining it, and they were also not on an inexorable downward slope.
That combination — real but usually temporary — is the single most useful thing to know, and it is almost never what a woman finds when she searches her symptoms at two in the morning.
What Is Actually Happening in the Brain
The brain is an estrogen-responsive organ. Estradiol receptors are densely distributed in the hippocampus and prefrontal cortex — the regions that handle memory formation, verbal retrieval, and executive function. These are precisely the domains women describe losing.
Estradiol influences several things that bear directly on cognition: cerebral glucose metabolism, cholinergic signaling, synaptic plasticity, and cerebral blood flow. When estradiol production becomes erratic in perimenopause — and the defining feature of perimenopause is volatility, not simply decline — the brain is adapting to a moving target.
Neuroimaging work over the past decade has shown measurable shifts in brain glucose metabolism across the menopausal transition, along with other changes in brain energetics. This research has been important in establishing that the menopausal transition is a neurological event and not solely a reproductive one.
Two cautions, because this literature is frequently overstated in popular coverage. First, imaging findings describe group-level changes over time; they are not a diagnostic test and cannot be applied to an individual woman’s scan. Second, and more importantly: demonstrating that the brain changes during menopause is not the same as demonstrating that menopause causes Alzheimer’s disease. Women’s higher lifetime dementia risk relative to men is real, and hormonal transition is one hypothesis among several — including longevity, differential vascular risk, and APOE4 interactions — for why.
What Usually Drives the Fog
In clinical practice, when I work through cognitive complaints in perimenopausal women, the cause is frequently not the direct hormonal effect on neurons. It is one or more of the following, all of which respond to treatment.
Disrupted sleep
This is the dominant driver in most of the women I see. Night sweats fragment sleep, often without full awakening, so a woman reports sleeping seven hours while getting very little restorative deep sleep. Deep sleep is when the brain consolidates memory and clears metabolic waste. Take it away for two years and cognition suffers in exactly the pattern women describe.
There is also a research finding worth knowing: objectively measured hot flashes — particularly nighttime ones — have been associated with poorer memory performance and with greater burden of white matter changes on MRI. Vasomotor symptoms may not be merely uncomfortable. See Sleep and Alzheimer’s: What the Research Actually Says.
New or worsening mood symptoms
The risk of a depressive episode rises substantially during perimenopause, including in women with no prior history. Depression and anxiety impair concentration, working memory, and retrieval — and produce a subjective sense of cognitive failure that is often more severe than objective testing shows. Treating the mood disorder frequently resolves “the memory problem.”
Iron deficiency
Heavy and irregular perimenopausal bleeding is a common cause of iron deficiency, and ferritin can be low enough to cause fatigue and cognitive fog well before hemoglobin falls into anemic range. A normal complete blood count does not rule this out. This is one of the most frequently missed and most easily corrected causes I encounter — ferritin should be checked in any woman with heavy bleeding and brain fog.
Thyroid dysfunction
Thyroid disease becomes more common in midlife women and produces overlapping symptoms. It is a simple test and worth doing once.
Load
Not a diagnosis, but not nothing. The perimenopausal years frequently coincide with career peak, adolescent children, and aging parents. Cognitive bandwidth is finite. This does not make the symptom imaginary — it makes it contextual, and it belongs in the assessment.
How to Tell Menopause Brain Fog from Early Alzheimer’s
This is the fear underneath the question, so let me address it directly. Certain features point toward the hormonal transition, and others should prompt a formal evaluation regardless of age.
More consistent with the menopausal transition:
- Fluctuating rather than steadily progressive — good days and bad days, worse when sleep is poor
- Word-finding difficulty and slowed retrieval, where the word arrives later
- Difficulty with divided attention and multitasking rather than forgetting events entirely
- You are far more concerned about it than the people around you are
- Daily function is preserved; work and household management continue
- It coincides with vasomotor symptoms, cycle changes, or new sleep disruption
Warrants formal evaluation:
- Steadily progressive decline over months without fluctuation
- Forgetting entire conversations or events, not just details — and not recovering them with cues
- Repeating the same question within a single conversation
- Getting lost in familiar places or losing spatial orientation
- Family or colleagues are more worried than you are
- Difficulty with previously routine tasks — finances, medications, familiar procedures
- Onset well after menopause was complete, rather than during the transition
- Personality or judgment changes
For a fuller treatment, see Early Signs of Alzheimer’s vs. Normal Aging: How to Tell the Difference.
The practical point: the distinction is usually clear on formal cognitive testing, and formal testing is worth doing if the concern is significant. Ongoing uncertainty is itself a harm, and it is one that is straightforward to resolve.
Treatment Options That Actually Help
Hormone therapy: what it can and cannot do
Let me separate two claims that are constantly merged.
What hormone therapy does: it is the most effective available treatment for moderate to severe vasomotor symptoms. Where night sweats are fragmenting sleep and poor sleep is degrading cognition, treating the vasomotor symptoms frequently improves how a woman thinks and feels. That is a real cognitive benefit arriving through a very ordinary mechanism — she is finally sleeping.
What hormone therapy is not indicated for: preventing cognitive decline or dementia. The Menopause Society and other major bodies are explicit that hormone therapy should not be prescribed for that purpose. The evidence does not support it, and I do not prescribe it on that basis.
Formulation and route matter to the risk profile. Transdermal estradiol avoids first-pass hepatic metabolism and carries a lower venous thromboembolism risk than oral preparations. Micronized progesterone has a more favorable profile than the synthetic progestin used in the original Women’s Health Initiative trials. For genitourinary symptoms alone, low-dose vaginal estrogen delivers minimal systemic exposure — and has no cognitive indication.
The decision to use hormone therapy is individual and belongs with a clinician who knows your history, particularly regarding breast cancer, cardiovascular disease, and clotting risk. It is a reasonable, evidence-based treatment for symptoms. It is not a brain-protection strategy.
Non-hormonal treatment of hot flashes and night sweats
Effective options now exist for women who cannot or prefer not to use hormones.
Neurokinin receptor antagonists represent the meaningful recent advance — fezolinetant, approved in 2023, and elinzanetant, approved in late 2025, target the hypothalamic pathway that generates vasomotor symptoms. They are genuinely effective and non-hormonal. Fezolinetant requires liver monitoring, and prescribing information reflects reports of serious liver injury; this should be discussed and followed.
Older non-hormonal options remain useful: certain SSRIs and SNRIs, gabapentin at bedtime for nighttime symptoms, and oxybutynin. None are as effective as hormone therapy for vasomotor symptoms, but all can help meaningfully.
Cognitive behavioral therapy for insomnia
If sleep is the driver — and it usually is — CBT-I is the first-line treatment for chronic insomnia, with durability that sleep medications do not match. It is underused because it requires referral and effort rather than a prescription. It is, in my experience, the highest-yield non-hormonal intervention for perimenopausal cognitive complaints.
Screening for obstructive sleep apnea is also essential here. Apnea risk rises sharply after menopause, and it presents differently in women — fatigue, insomnia, and morning headache rather than classic loud snoring — so it is routinely missed in women who do not fit the stereotype.
Exercise, with resistance training included
Regular aerobic exercise improves sleep quality, mood, vasomotor symptom burden, and cerebral perfusion. Resistance training addresses the accelerated loss of muscle and bone that accompanies estrogen decline and improves insulin sensitivity, which is itself relevant to long-term cognitive risk. This is the intervention with the broadest benefit across every mechanism discussed in this article.
Treating mood, and treating it properly
If depression or anxiety is present, treat it as a primary condition rather than as an expected feature of menopause. The cognitive improvement that follows adequate treatment is often substantial.
Cardiometabolic risk, which is where the long game is
The menopausal transition brings adverse shifts in lipids, blood pressure, visceral adiposity, and insulin sensitivity. These changes are the strongest link between midlife in women and later cognitive risk, and unlike the transient fog, they are cumulative. If you take one long-term action from this article, it should be getting blood pressure and metabolic health measured and managed now. See The 40%: What Modifiable Risk Factors Mean for Dementia Prevention.
Why the Studies on Hormone Therapy and Dementia Disagree
Women researching this topic encounter flatly contradictory headlines. The contradiction is explicable.
The Women’s Health Initiative Memory Study reported in the early 2000s that hormone therapy increased dementia risk, and that finding reshaped practice for two decades. The details matter: participants were women aged 65 and older, on average more than a decade past menopause, receiving oral conjugated equine estrogens with a synthetic progestin. It was not a study of a 50-year-old starting transdermal estradiol for night sweats, and it was never designed to answer that question.
The timing hypothesis emerged in response: that hormone therapy initiated near the onset of menopause may have different effects than therapy started years later, when vascular and neural tissue has already changed. It is biologically plausible and has some support in cardiovascular research.
Trials designed to test it found neither harm nor benefit for cognition. The KEEPS trial, which enrolled recently menopausal women, found no cognitive benefit and no cognitive harm over four years; long-term follow-up roughly a decade later similarly found no lasting effect in either direction. The ELITE trial, examining early versus late initiation, likewise found no cognitive advantage.
Large registry studies continue to conflict. Some national database analyses report associations between hormone therapy and later dementia, including among younger users. These studies face a fundamental problem called confounding by indication: women who take hormone therapy differ systematically from women who do not — most relevantly, they have more severe vasomotor symptoms, which are themselves associated with cognitive and vascular risk. An observational association cannot separate the drug from the reason it was prescribed.
Where this leaves an honest clinician: hormone therapy started near menopause for symptom relief does not appear to protect cognition, and does not appear to harm it. It should be chosen or declined based on symptoms, risk profile, and preference — not on a dementia-prevention rationale in either direction.
If You Carry APOE4
Women carrying APOE4 appear to face higher risk than men carrying the same genotype, with the difference most pronounced in the years following menopause. Some research suggests the menopausal transition interacts with APOE4 in ways that may accelerate amyloid-related changes.
What this does not yet support is a different hormone therapy recommendation based on genotype. The data are not adequate to individualize that decision, and anyone offering you a genotype-specific hormone protocol is ahead of the evidence.
What it does support is treating the menopausal transition as the right moment for a genuine cognitive risk assessment in a woman who carries APOE4 — baseline cognitive testing, blood pressure, metabolic markers, sleep evaluation. See I Have APOE4 but No Symptoms. What Should I Do Next?
What an Evaluation Should Include
If cognitive symptoms during the transition are significant enough to bring you to a clinician, a reasonable workup includes:
- Formal cognitive testing sensitive enough to detect subtle change — not a brief screen
- Thyroid function, B12, ferritin and full iron studies, vitamin D, hemoglobin A1c and fasting insulin
- A complete lipid panel and properly measured blood pressure
- Screening for depression, anxiety, and sleep disorders, including obstructive sleep apnea
- Review of medications, including anticholinergic burden, which is frequently overlooked
- Alcohol assessment — tolerance and sleep effects often change during this period
- Brain MRI where symptoms are progressive, focal, or atypical
Most of the time, this evaluation finds one or two correctable contributors and delivers a clear answer. That answer is the treatment for the fear, which is often as disabling as the fog.
Common Questions
Is brain fog during perimenopause permanent?
For most women, no. Cognitive testing shows declines in verbal memory and processing speed during the transition with substantial recovery in postmenopause. Persistent or progressive decline is not an expected feature of menopause and warrants evaluation.
Does menopause cause Alzheimer’s disease?
No. The menopausal transition produces measurable changes in brain metabolism and structure, and women carry higher lifetime dementia risk than men, but menopause has not been shown to cause Alzheimer’s disease. Multiple explanations for the sex difference exist, including longevity, vascular risk, and genetic interactions.
Does hormone therapy improve memory?
Hormone therapy has not been shown to improve cognition directly. It can improve cognitive function indirectly when it relieves hot flashes and night sweats that are disrupting sleep. It is not indicated for treating or preventing cognitive decline.
Does hormone therapy prevent dementia?
No. Major professional societies recommend against prescribing hormone therapy for dementia prevention. Randomized trials in recently menopausal women found neither cognitive benefit nor harm. Older trials in women well past menopause found increased dementia risk with specific oral formulations.
What helps menopause brain fog without hormones?
Treating the underlying drivers: cognitive behavioral therapy for insomnia, evaluation and treatment of sleep apnea, non-hormonal medications for vasomotor symptoms such as neurokinin receptor antagonists, correction of iron and thyroid abnormalities, treatment of depression or anxiety, and regular aerobic plus resistance exercise.
When should I worry that it is not menopause?
Seek evaluation for steadily progressive decline, forgetting entire events or conversations, repeating questions within a conversation, getting lost in familiar places, difficulty with previously routine tasks, or when family members are more concerned than you are.
Can low iron cause memory problems in perimenopause?
Yes. Heavy perimenopausal bleeding commonly causes iron deficiency, and low ferritin can cause fatigue and cognitive fog before anemia appears on a standard blood count. Ferritin should be checked specifically; a normal complete blood count does not rule it out.
The Bottom Line
What women in this phase most need is neither dismissal nor alarm. The cognitive symptoms are real and measurable, they are usually temporary, and the specific things driving them — fragmented sleep, mood changes, iron deficiency, thyroid dysfunction, untreated apnea — are identifiable and treatable.
Hormone therapy is an effective treatment for symptoms and a poor argument for brain protection. The things that genuinely change long-term cognitive trajectory in women are the unglamorous ones: blood pressure, metabolic health, sleep, exercise, and hearing, managed consistently from midlife onward.
The women I worry about are not the ones who come in frightened about their memory. They are the ones who were told this was simply their age, and who never had anyone check.
Dr. Nadir Bilici is a double board-certified neurologist and lifestyle medicine physician specializing in preventive neurology, Alzheimer’s prevention, and cognitive risk assessment. He sees patients via telehealth nationwide and in person in New York City.
This article is for educational purposes and does not constitute medical advice. Decisions about hormone therapy and other treatments should be made with a qualified clinician who knows your full medical history.
Published September 2026 · Medically reviewed by Nadir Bilici, MD, DipIBLM. See our editorial policy.